Chemotactic Factors as Mediators of Allergy

  • B. M. Czarnetzki


Mast cells are the central effector cells of acute allergic reactions. Besides histamine which has no significant chemotactic activity of its own, mast cells release other inflammatory mediators into their environment. Several of these factors have neutrophil or eosinophil chemotactic activities, such as leukotriene B4 (LTB4), platelet activating factor (PAF) and neutrophil chemotactic factor (NCF). Enzymes of mast cells can also activate the complement casade, resulting in the production of the potent chemotactic peptide C 5 a. Once inflammatory leukocytes have entered the site of allergic reaction, they can generate the same chemotactic mediators that are produced by mast cells. Chemotactic mediators serve to amplify and perpetuate mast cell-dependent allergic processes, and they induce chronic inflammatory changes and tissue damage in persistent, severe allergic reactions.


Mast Cell Platelet Activate Factor Chemotactic Factor Chemotactic Activity Glyceryl Ether 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Altman LC (1978) Chemotactic lymphokines: a review. In: Gallin JI, Quie PG (eds) Leukocyte Chemotaxis. Raven, New York, pp 267–267Google Scholar
  2. 2.
    Berrens L (1981) Struktur und Eigenschaften der atopischen Allergene. Hautarzt [Suppl 54] 32: 83–85Google Scholar
  3. 3.
    Cundell DR, Moodley I, Davies RJ (1984) Properties of a high molecular weight neurophil chemotactic factor, possibly derived from mast cells: evidence for chemokinetic rather than chemotactic activity. Agents Actions 14: 384–387CrossRefGoogle Scholar
  4. 4.
    Clark AF, Gallin JI, Kaplan AP (1975) The selective eosinophil chemotactic activity of histamine. J Exp Med 142: 1462–1476PubMedCrossRefGoogle Scholar
  5. 5.
    Czarnetzki BM (1980) Low molecular weight eosinophil chemotactic factor (ECF) production by rat peritoneal mononuclear phagocytes. Immunobiology 157: 62–66PubMedGoogle Scholar
  6. 6.
    Czarnetzki BM (1981) In vitro generation of eosinophil chemotactic factor (ECF) from human and murine mononuclear phagocytes. Scand J Immunol 13:511 –516PubMedCrossRefGoogle Scholar
  7. 7.
    Czarnetzki BM (1983) Increased monocyte Chemotaxis towards leukotriene B4 and platelet activating factor in psoriasis and atopic eczema. Clin Exp Immunol 54:486–492Google Scholar
  8. 8.
    Czarnetzki BM (1985) Combined effect of chemotactic factors on in vitro leukocyte Chemotaxis. J Invest Dermatol 84: 444 (Abstract)Google Scholar
  9. 9.
    Czarnetzki BM (1985) Chemotaktische Mediatoren. Allergologie 8: 63–68Google Scholar
  10. 10.
    Czarnetzki BM, Benveniste J (1981) Effect of synthetic PAF-acether in human neutrophil leukocytes. I. Analysis of the in vitro migration of human neutrophils. Chem Phys Lipids 29: 317–326PubMedCrossRefGoogle Scholar
  11. 11.
    Czarnetzki BM, Frosch PJ, Mardin M (1983) Leukotriene B4 and neutrophil-derived eosinophil chemotactic factor: Comparison of their biological activities. Monogr Allergy 18: 193–195CrossRefGoogle Scholar
  12. 12.
    Czarnetzki BM, König W, Lichtenstein LM (1975) Release of eosinophil chemotactic factor from human polymorphonuclear neutrophils by calcium ionophore A 23187 and phagocytosis. Nature 258: 725–726CrossRefGoogle Scholar
  13. 13.
    Czarnetzki BM, Meentken J, Kolde G, Bröcker EB (1985) Morphology of the cellular in-filtrate in delayed pressure urticaria. J Am Acad Dermatol 12:253–259Google Scholar
  14. 14.
    Czarnetzki BM, Mertensmeier R (1985) In vitro and in vivo Chemotaxis of guinea pig leukocytes towards leukotriene B4 and its co-oxidation products. Prostaglandins 30: 5–12PubMedCrossRefGoogle Scholar
  15. 15.
    Czarnetzki BM, Panneck W, Frosch PJ (1980) Inhibitory effect of heparin on leukocyte chemotactic factors. Clin Exp Immunol 39: 526–531PubMedGoogle Scholar
  16. 16.
    Czarnetzki BM, Zimmermann RE, Fischer N (1981) Further characterization of the neutrophil-derived eosinophil chemotactic factor and comparison to eosinophil chemotactic activity from mast cells. Int Arch Allergy Appl Immunol 66 (S): 172–173CrossRefGoogle Scholar
  17. 17.
    Fink JN (1985) Allergic bronchopulmonary aspergillosis. Chest 87:81 S–84SPubMedGoogle Scholar
  18. 18.
    Ford-Hutchinson AW (1984) Leukotriene involvement in pathological processes. J Allergy Clin Immunol 74 (S): 437–440PubMedCrossRefGoogle Scholar
  19. 19.
    Gorman EE, Morton DR, Hopkins NK, Lin AH (1983) Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis and cyclic AMP accumulation in human polymorphonuclear leukocytes. In: Samuelsson B, Paoletti R, Ramwell P (eds) Advances in prostaglandin, thromboxane, and leukotriene research, vol 12. Raven, New York, pp 57–63Google Scholar
  20. 20.
    Grabbe J, Czarnetzki BM, Mardin M (1984) Release of lipoxygenase products of arachidonic acid from freshly isolated human keratinocytes. Arch Dermatol Res 276: 128–130PubMedCrossRefGoogle Scholar
  21. 21.
    Ishizaka T, Iwata M, Ishizaka R (1985) Release of histamine and arachidonate from mouse mast cells induced by glycosylation-enhancing factor and bradykinin. J Immunol 134: 1880–1887PubMedGoogle Scholar
  22. 22.
    Kaliner M (1985) Mast cell mediators and asthma. Chest 87:2 S–5 SGoogle Scholar
  23. 23.
    Kownatzki E, Kapp A, Uhrich S (1985) Novel neutrophil chemotactic factor derived from human monocytes. J Invest Dermatol 84: 444 (Abstract)Google Scholar
  24. 24.
    Lemanske RF, Guthman DA, Kaliner M (1983) The biologic activity of mast cell granules. VII. The effect of anti-neutrophil antibody-induced neutropenia on rat cutaneous late phase reactions. J Immunol 131: 929–933PubMedGoogle Scholar
  25. 25.
    Mensing H, Czarnetzki BM (1984) Leukotriene B4 induces in vitro fibroblast chemotaxis. J Invest Dermatol 82:9– 12Google Scholar
  26. 26.
    Nagy L, Lee TH, Kay AB (1982) Neutrophil chemotactic activity in antigen-induced late asthmatic reactions. N Engl J Med 306: 497–501PubMedCrossRefGoogle Scholar
  27. 27.
    Nathbony SF, Phillips ME, Elias JM, Godfrey HP, Kaplan AP (1983) Histologic studies of chronic idiopathic urticaria. J Allergy Clin Immunol 71:177– 183Google Scholar
  28. 28.
    Oertel HL, Kaliner M (1981) The biologic activity of mast cell granules. III. Purification of inflammatory factors of anaphylaxis ( IF-A) responsible for causing late-phase reactions. J Immunol 127: 1398–1402PubMedGoogle Scholar
  29. 29.
    Rosenbach T, Grabbe J, Moller A, Schwanitz HJ, Czarnetzki BM (1985) Generation of leukotrienes from normal epidermis and their demonstration in cutaneous disease. Br J Dermatol 113 (285) 157–167PubMedCrossRefGoogle Scholar
  30. 30.
    Roubin R, Mencia-Huerta JM, Benveniste J (1982) Release of platelet-activating factor ( PAF acether) and leukotrienes C and D from inflammatory macrophages. Eur J Immunol 12: 141–146PubMedCrossRefGoogle Scholar
  31. 31.
    Ruzicka T, Simmet T, Peskar BA, Braun-Falco O (1984) Leukotrienes in skin of atopic dermatitis. Lancet 1: 222–223PubMedCrossRefGoogle Scholar
  32. 32.
    Samuelsson B (1982) The leukotrienes. An introduction. In: Samuelsson B, Paoletti R (eds) Leukotrienes and other lipoxygenase products. Raven, New York, pp 1–17Google Scholar
  33. 33.
    Wassermann SI, Soter NA, Center DM, Austen KF (1977) Cold urticaria: recognition and characterization of a neutrophil chemotactic factor which appears in serum during experimental cold challenge. J Clin Invest 60: 189–196CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • B. M. Czarnetzki
    • 1
  1. 1.Universitäts-Hautklinik MünsterMünsterFederal Republic of Germany

Personalised recommendations